Enrollment Passes Halfway Milestone in Clinical Trial Evaluating the Effect of an Exclusive Human Milk Diet Including a Specialty Fortifier in Term Infants Born with Single Ventricle Congenital Heart Defects
Type: Press Releases
Topic(s): Single Ventricle Congenital Heart Defects (SVP )
New Analysis Published in the Journal Breastfeeding Medicine Finds Additional Clinically Significant Benefits From an Exclusive Human Milk Diet in the NICU
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Cost Savings / Cost Effectiveness Necrotizing Entercolitis (NEC) Product Total Parenteral Nutrition (TPN) Use
Starting 100 Percent Human Milk-Based Fortifier Early Is Associated With Improved Growth in Extremely Premature Infants, According to an Independent Study
Type: Press Releases
Topic(s): Growth Healthcare Professionals Necrotizing Entercolitis (NEC) Neurodevelopmental Outcomes
Prolacta Bioscience Salutes World Breast Milk Donation Day May 19
Type: Press Releases
Topic(s):
Prolacta Bioscience to Present at the Cowen and Company 38th Annual Health Care Conference on March 14, 2018
Type: Press Releases
Topic(s): Conferences and Events
Prolacta Bioscience Earns LEED Gold Certification for New Headquarters in Duarte
Type: Press Releases
Topic(s): Company
Prolacta Bioscience Launches Easier-to-Read Labels for its Human Milk-Based Neonatal Nutritional Products
Type: Press Releases
Topic(s): Product
Prolacta Bioscience Supports Prematurity Awareness Month with New Educational Resources for Parents of Preemies
Type: Press Releases
Topic(s): Late-Onset Sepsis Necrotizing Entercolitis (NEC)
Prolacta Bioscience to Participate in Panel Addressing Clinical Quality and Safety of Exclusive Human Milk During National Coalition for Infant Health Policy Summit
Type: Press Releases
Topic(s): Advocacy Pasteurization Quality & Safety